Bausch Health Companies share price today

Bausch Health Companies Inc.'s share price was $8.34 at the close on 4 November 2026. It has been stalling near its high for 6 weeks. That is 45.8% above its average price over the last 200 trading days.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Bausch Health Companies Inc. is in stage 3. The phase helps read everything below.

In the last 52 weeks it traded between $4 and $8, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 15 weeks in a row.

Over the last 10 years the share price moved −64% while the S&P 500 moved +261%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Bausch Health Companies Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Bausch Health Companies is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Bausch Health Companies Inc. earned $258 M of net profit in the Jun 2026 quarter, +74.3% on the same quarter a year earlier. Full-year FY25 profit was $157 M. That is 9.0% of the quarter's revenue. The same quarter a year earlier earned $148 M. 7 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Bausch Health Companies Inc. reported $2.9 B of revenue in the Jun 2026 quarter, +12.7% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 5.0% a year on average. The last full year, FY25, came in at $10.3 B.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $10.9 B.

FY25 revenue was $10.3 B, +6.7% on the year before.

Recent pace: the last four quarters grew +10.1% on average, against 5.0% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +10.1%, against +8.6% a year over the last 8 quarters (stabilising).

Bausch Health Companies Inc.'s operating margin was 27.2% in the Jun 2026 quarter, 9.1 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 18.3% and 21.4%. The latest quarter is above every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Across 5 years it has been between 18.3% and 21.4%, and FY25's 21.4% is the highest of them.

Why the margin moved: operating margin changed +9.1 percentage points on the year while gross margin changed +3.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Bausch Health Companies Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $1.4 B of operating cash against $157 M of profit. After $397 M of spending on assets, $1.0 B was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Bausch Health Companies Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $949 M on assets over the last 3 years. Averaged over those years that is 3.1% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $949 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Bausch Health Companies Inc.'s P/E is 16.4×, near the high end of its own history: higher than 72% of past readings. Its usual P/E (the middle reading) is 12.0×, over 4.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Bausch Health Companies Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Bausch Health Companies Inc. earned a ROE of 42% in FY25. That is up from a low of −87% in FY22. Its return on capital used (ROIC) is 8.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 1.5% net margin and 0.39× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 1.5% net margin × 0.39× asset turnover × 69.94× leverage (assets divided by equity) ≈ 40.9% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 14.7% − 6.0% = +8.7 percentage points. The 6.0% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value.

The 14.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 3.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Bausch Health Companies Inc.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from −674.06 in FY21 to 55.91 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.